Kazia Therapeutics Limited (KZIA)
NASDAQ: KZIA · Real-Time Price · USD
14.22
+0.30 (2.16%)
Jun 26, 2026, 4:00 PM EDT - Market closed
Kazia Therapeutics Employees
Kazia Therapeutics had 6 employees as of June 30, 2025. The number of employees decreased by 1 or -11.76% compared to the previous year.
Employees
6
Change (1Y)
-1
Growth (1Y)
-11.76%
Revenue / Employee
$211,072
Profits / Employee
-$2,534,761
Market Cap
162.49M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2025 | 6 | -1 | -11.76% |
| Jun 30, 2024 | 7 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| ProQR Therapeutics | 187 |
| Humacyte | 184 |
| Innate Pharma | 164 |
| Caribou Biosciences | 97 |
| Tenaya Therapeutics | 70 |
| Acumen Pharmaceuticals | 61 |
| Pyxis Oncology | 56 |
| Milestone Pharmaceuticals | 38 |
KZIA News
- 17 days ago - Kazia Therapeutics initiated with a Buy at Lake Street - TheFly
- 26 days ago - Kazia Therapeutics appoints James Levine as CFO - TheFly
- 26 days ago - Kazia Therapeutics Appoints James Levine as Chief Financial Officer - PRNewsWire
- 4 weeks ago - Kazia Therapeutics Expands Ongoing Phase 1b Trial of Paxalisib in Advanced Breast Cancer - PRNewsWire
- 2 months ago - Kazia Therapeutics appoints Sudha Rao as Chief Scientific Officer - TheFly
- 2 months ago - Kazia Therapeutics Strengthens Scientific Leadership with Appointment of Dr. Sudha Rao as Chief Scientific Officer to Lead Next-Generation Oncology Platform - PRNewsWire
- 2 months ago - Kazia Therapeutics initiated with a Buy at Laidlaw - TheFly
- 2 months ago - Kazia Therapeutics in-licenses drug development platform from QIMR Berghofer - TheFly